The cobas c 513 analyzer from Roche - high-volume HbA1c testing for US labs
01.07.2026 - 07:03:51 | ad-hoc-news.de
By Nora Whitfield, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 1:10 AM ET. Details in the imprint.
The cobas c 513 analyzer sits behind a glass panel in a suburban Boston lab, its status lights pulsing soft green as racks of blood tubes slide into place. Technologist Michael Harris leans in to check the touchscreen, watching HbA1c results tick up in real time.
High-throughput HbA1c workhorse
Roche’s cobas c 513 is a dedicated HbA1c analyzer designed for high-volume laboratories that need fast and standardized diabetes testing. According to Roche Diagnostics, the system can deliver up to 400 HbA1c results per hour using turbidimetric inhibition immunoassay technology.
The instrument is built on Roche’s cobas platform and is intended for use with EDTA whole blood samples, offering automated sample handling from primary tubes and minimizing manual pipetting. In practice, that means fewer hands-on steps for lab staff during busy morning draw windows.
US positioning and regulatory status
Roche markets the cobas c 513 analyzer in the United States for use in medium to large routine clinical laboratories that require HbA1c for diabetes diagnosis and monitoring. The company highlights that the system aligns with NGSP and IFCC standardization frameworks, supporting consistent results across sites.
In its US materials, Roche emphasizes that the cobas c 513 is intended for professional use and is not a point-of-care device; samples flow from collection centers into centralized labs, where the analyzer sits alongside chemistry and immunoassay systems. The product fits into Roche’s broader integrated diagnostics strategy that combines instruments, reagents, and data solutions.
Roche diagnostics in investor focus
Read more background on Roche Holding stock and its diagnostics segment performance in our dedicated topic channel.
Workflow, maintenance and lab experience
From the user side, the cobas c 513 is a full-size bench analyzer with an enclosed measuring area, central touchscreen, and front-loading sample racks. On the Roche product page, the company states that it offers 72 positions for routine samples plus dedicated STAT positions for urgent work.
In everyday operation, technologists like Harris load barcoded tubes, confirm worklists on the screen, and monitor controls at defined intervals. The analyzer’s internal mixing and reagent dispensing are automated, but labs still need to handle routine maintenance such as reagent replacement, calibration runs, and cleaning cycles as specified in Roche’s documentation.
Reagents, quality and interoperability
Roche supplies HbA1c reagents and controls specifically calibrated for the cobas c 513, with kit sizes targeted at high-volume labs that run thousands of tests per week. The company’s materials underline that the assay is certified by the NGSP program and traceable to IFCC reference methods. For US labs, that certification is a practical requirement for reporting HbA1c in diabetes diagnosis.
On the data side, Roche notes that the analyzer interfaces with laboratory information systems (LIS) over standard protocols, allowing HbA1c results to flow into electronic health records without manual transcription. In larger networks, cobas c 513 units may sit under Roche’s cobas infinity or third-party middleware, which manage routing and overall instrument utilization.
Context, competition and stock
Within Roche Holding, the cobas c 513 falls under the Diagnostics division, which includes immunoassay, clinical chemistry, and molecular systems. Rival offerings for high-throughput HbA1c testing come from companies such as Abbott and Siemens Healthineers, meaning US labs can choose among several platforms when planning upgrades.
Roche Holding stock (SIX: ROG, ISIN CH0012032048) is listed on the SIX Swiss Exchange and tracked in the Swiss Market Index, where diagnostics products like the cobas c 513 contribute alongside the company’s large pharmaceutical portfolio.
Key facts on cobas c 513
- Product: cobas c 513 analyzer
- Manufacturer: Roche Holding AG
- Category: Accessories & diagnostic components (Wednesday module)
- Launch: Introduced as part of Roche’s dedicated HbA1c platform line; available in US and EU markets in the mid-2010s.
- MSRP / Price: Pricing is negotiated per lab contract; industry sources indicate high five-figure to low six-figure USD ranges for analyzer plus reagent commitments.
- Availability: Commercially available to clinical laboratories in the United States and internationally via Roche Diagnostics sales channels.
- Target audience: Hospital and commercial labs processing high volumes of HbA1c tests for diabetes diagnosis and monitoring.
- Standout / USP: Dedicated high-throughput HbA1c analyzer delivering up to 400 results per hour with NGSP-certified, IFCC-traceable assays on the cobas platform.
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
